British Ophthalmological Surveillance Unit obtains further funding

Article

Fight for Sight has given further funding to the British Ophthalmological Surveillance Unit (BOSU) for research into preventing sight loss and treating eye disease.

Fight for Sight has given further funding to the British Ophthalmological Surveillance Unit (BOSU) for research into preventing sight loss and treating eye disease.

BOSU provides ophthalmologists with a Reporting Card so they can alert researchers to uncommon eye disease cases. The data collected goes towards research projects investigating rare eye disorders.

Dr Rashmi Matthew, who used BOSU to develop the British Ocular Syphillis Study, said, "BOSU has been invaluable in furthering our understanding of ocular syphilis- a rare form of the sexually transmitted disease. Through the support of Fight for Sight and the Royal College of Ophthalmologists, many more researchers will benefit from this essential resource, expanding our knowledge of rare eye conditions and disorders.”

Chief Executive of Fight for Sight, said, “Ophthalmologists play a vital role in the identification and reporting of uncommon eye diseases, as well as rare complications of more common eye conditions, and their participation in BOSU has a huge impact on medical research into eye disease. Through our work with BOSU, we hope to inspire even more people to help raise awareness within the medical profession of the less common conditions under investigation.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.